1 week Ago By Defense World Staff
Geode Capital Management LLC lifted its stake in shares of Tandem Diabetes Care, Inc. ( NASDAQ:TNDM – Free Report ) by 0.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission.
The fund owned 1,533,828 shares of the medical device company’s stock after purchasing an additional 8,012 shares during the quarter. Geode Capital Management LLC owned 2.34% of Tandem Diabetes Care worth $55,261,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also added to or reduced their stakes in TNDM. Vanguard Group Inc. increased its holdings in shares of Tandem Diabetes Care by 1.
1% during the fourth quarter. Vanguard Group Inc. now owns 7,440,005 shares of the medical device company’s stock worth $267,989,000 after buying an additional 77,451 shares in the last quarter.
State Street Corp increased its holdings in Tandem Diabetes Care by 3.2% in the 3rd quarter. State Street Corp now owns 2,655,736 shares of the medical device company’s stock worth $112,630,000 after purchasing an additional 83,172 shares in the last quarter.
GW&K Investment Management LLC raised its position in Tandem Diabetes Care by 18.0% in the fourth quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company’s stock valued at $76,488,000 after purchasing an additional 323,674 shares during the last quarter.
Stephens Investment Management Group LLC boosted its stake in shares of Tandem Diabetes Care by 22.1% during the fourth quarter. Stephens Investment Management Group LLC now owns 1,555,809 shares of the medical device company’s stock valued at $56,040,000 after purchasing an additional 281,327 shares in the last quarter.
Finally, Paradice Investment Management LLC grew its holdings in shares of Tandem Diabetes Care by 5.9% during the fourth quarter. Paradice Investment Management LLC now owns 956,407 shares of the medical device company’s stock worth $34,450,000 after purchasing an additional 52,966 shares during the last quarter.
Analyst Upgrades and Downgrades Several equities research analysts recently commented on TNDM shares. Citigroup downgraded shares of Tandem Diabetes Care from a “buy” rating to a “neutral” rating and cut their target price for the stock from $35.00 to $24.
00 in a research report on Tuesday, March 4th. Morgan Stanley cut shares of Tandem Diabetes Care from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $45.00 to $22.
00 in a research note on Wednesday, March 5th. Mizuho began coverage on Tandem Diabetes Care in a research report on Thursday. They set a “neutral” rating and a $20.
00 target price for the company. The Goldman Sachs Group reduced their price target on Tandem Diabetes Care from $42.00 to $24.
00 and set a “neutral” rating on the stock in a research report on Monday, March 3rd. Finally, Robert W. Baird decreased their price target on Tandem Diabetes Care from $37.
00 to $33.00 and set a “neutral” rating for the company in a research note on Thursday, February 27th. Nine research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock.
Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $43.88.
Insider Activity at Tandem Diabetes Care In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos purchased 10,538 shares of Tandem Diabetes Care stock in a transaction that occurred on Friday, March 7th. The stock was acquired at an average price of $18.12 per share, with a total value of $190,948.
56. Following the transaction, the chief operating officer now owns 10,538 shares in the company, valued at $190,948.56.
This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website . 2.
20% of the stock is currently owned by corporate insiders. Tandem Diabetes Care Price Performance Shares of NASDAQ TNDM opened at $17.06 on Monday.
The firm has a market capitalization of $1.13 billion, a P/E ratio of -8.84 and a beta of 1.
52. The firm’s 50-day moving average price is $23.62 and its 200-day moving average price is $30.
82. The company has a current ratio of 2.90, a quick ratio of 2.
32 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care, Inc.
has a 1-year low of $15.75 and a 1-year high of $53.69.
Tandem Diabetes Care Company Profile ( Free Report ) Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. Featured Stories Five stocks we like better than Tandem Diabetes Care How the NYSE and NASDAQ are Different, Why That Matters to Investors Is McDonald’s Stock Serving a Value Meal to Investors? Stock Market Sectors: What Are They and How Many Are There? Walgreens Comeback? Private Equity Circling for a Buyout Why Invest in High-Yield Dividend Stocks? Coca-Cola Stock Looks Refreshing After the Relief Rally Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.
com's FREE daily email newsletter ..
